Long COVID is associated with severe cognitive slowing: a multicentre cross-sectional study

Zhao, Sijia; Martin, Eva Maria; Reuken, Philipp A.; Scholcz, Anna; Ganse-Dumrath, Akke; Srowig, Annie; Utech, Isabelle; Kozik, Valeska; Radscheidt, Monique; Brodoehl, Stefan; Stallmach, Andreas; Schwab, Matthias; Fraser, Emily; Finke, Kathrin; Husain, Masud

doi:10.1016/j.eclinm.2024.102434

Cited by 26 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, this hypothesis needs further investigation. Other authors have studied 194 patients with mild or severe COVID-19 and also explored the MoCA-BLIND test, finding cognitive impairment in 12.6% of patients [ 28 ]. The assessment of cognitive impairment was compared with other groups (patients with COVID-19 without persistent symptoms and patients without COVID-19), but did not use the same evaluation tool in the same group of patients at baseline and at the end of the study.…”

Section: Discussionmentioning

confidence: 99%

Preventive Intake of a Multiple Micronutrient Supplement during Mild, Acute SARS-CoV-2 Infection to Reduce the Post-Acute COVID-19 Condition: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial

Tomasa-Irriguible,

Monfà,

Miranda-Jiménez

et al. 2024

Nutrients

View full text Add to dashboard Cite

Patients hospitalized with COVID-19 have low levels of vitamins and trace elements. This could lead to a post-acute COVID-19 condition (PCC) that can worsen a patient’s quality of life. We aimed to study the baseline micronutrient status of patients and assess whether a multiple micronutrient supplement (MMS) taken for 2 weeks at the first sign of COVID-19 symptoms would be able to reduce the incidence of PCC. This double-blind, placebo-controlled, randomized clinical trial was conducted in adult outpatients with acute COVID-19, recruited between 2021 and 2023 in Spain. Of the 285 patients assessed for eligibility, 267 were randomized and 246 were included in the intent-to-treat population. The mean age was 46.8 years, and 68% were female. Overall, 54.6% had micronutrient deficiencies in the acute phase of COVID-19 at baseline, and 26.2% had PCC after 180 days of follow-up (D180). The most frequently recorded PCC symptoms were neurological (14.1%), with 24% patients scoring worse in the cognitive tests compared to their baseline status. The rate of PCC at D180 was similar between the placebo (25.0%) and intervention (27.7%) groups, without significant differences (p = 0.785). Age over 50 years was the most relevant risk factor for developing PCC, followed by female sex. The most important protective factor against PCC was SARS-CoV-2 vaccination. In this population of predominantly middle-aged, white women with acute COVID-19 not requiring hospital admission, MMS intake for 14 days at symptom onset did not prevent PCC nor improve their micronutrient status at D180.

show abstract

Section: Discussionmentioning

confidence: 99%

Preventive Intake of a Multiple Micronutrient Supplement during Mild, Acute SARS-CoV-2 Infection to Reduce the Post-Acute COVID-19 Condition: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial

Tomasa-Irriguible,

Monfà,

Miranda-Jiménez

et al. 2024

Nutrients

View full text Add to dashboard Cite

show abstract

“…Zeichen einer kraniozervikalen Instabilität (CCI) [ 103 ] e) Abklärung des Tethered-Cord-Syndroms (TCS) : Sakrale Grübchen/Haaren, evtl. LWS-MRT in Bauchlage (wenn verfügbar) [ 104 ] f) Abklärung eines POTS (mögliche Erklärung für Kopf- und Nackenschmerzen) (siehe auch „autonome Manifestationen“) [ 102 , 105 ] g) Abklärung von Mastzellüberaktivität/MCAS als mögliche Ursache für Kopf- und andere Schmerzen [ 102 , 106 ] Neurologische/kognitive Manifestationen Kurzzeitgedächtnis-, Konzentrationsstörungen, Aufmerksamkeitsstörungen, „brain fog“, Wortfindungsstörungen, Reizempfindlichkeit (Licht, Geräusche Berührungen), Ataxien, Muskelzuckungen, Muskelschwäche MBSQ [ 75 ], Teil V MoCA-Test, [ 107 ] Reaktionszeit-Test [ 108 ] a) Differentialdiagnostik/Abgrenzung anderer Ursachen von kognitiven Defiziten : [ 99 ] z. B. MS, Demenz cMRT, (Re‑)Infektionsdiagnostik, neurologische/psychiatrische Diagnostik b) Abgrenzung von sekundären, reaktiven psychischen Problemen/Störungen (z.…”

Section: Entstehung Und Zielsetzung Des D-a-ch-konsensusstatementsunclassified

Interdisziplinäres, kollaboratives D-A-CH Konsensus-Statement zur Diagnostik und Behandlung von Myalgischer Enzephalomyelitis/Chronischem Fatigue-Syndrom

Hoffmann,

Hainzl,

Stingl

et al. 2024

Wien Klin Wochenschr

View full text Add to dashboard Cite

ZusammenfassungMyalgische Enzephalomyelitis/Chronisches Fatigue-Syndrom (ME/CFS) ist eine schwere, chronische Multisystemerkrankung, die je nach Ausprägung zu erheblichen körperlichen und kognitiven Einschränkungen, zum Verlust der Arbeitsfähigkeit bis hin zur Pflegebedürftigkeit einschließlich künstlicher Ernährung und in sehr schweren Fällen sogar zum Tod führen kann. Das Ziel dieses D-A-CH-Konsensusstatements ist es, 1) den aktuellen Wissensstand zu ME/CFS zusammenzufassen, 2) in der Diagnostik die kanadischen Konsensuskriterien (CCC) als klinische Kriterien mit Fokus auf das Leitsymptom post-exertionelle Malaise (PEM) hervorzuheben und 3) vor allem im Hinblick auf Diagnostik und Therapie einen Überblick über aktuelle Optionen und mögliche zukünftige Entwicklungen aufzuzeigen. Das D-A-CH-Konsensusstatement soll Ärzt:innen, Therapeut:innen und Gutachter:innen dabei unterstützen, Patient:innen mit Verdacht auf ME/CFS mittels adäquater Anamnese und klinisch-physikalischen Untersuchungen sowie der empfohlenen klinischen CCC zu diagnostizieren und dabei die präsentierten Fragebögen sowie die weiteren Untersuchungsmethoden zu nutzen. Der Überblick über die zwei Säulen der Therapie bei ME/CFS, Pacing und die symptomlindernden Therapieoptionen sollen nicht nur Ärzt:innen und Therapeut:innen zur Orientierung dienen, sondern auch Entscheidungsträger:innen aus der Gesundheitspolitik und den Versicherungen darin unterstützen, welche Therapieoptionen bereits zu diesem Zeitpunkt bei der Indikation „ME/CFS“ von diesen erstattbar sein sollten.

show abstract

“…Two short web-based cognitive tasks were administered to patients with LC to examine cognitive slowing using Simple Reaction Time and Number Vigilance Tests. At two clinics in Germany and the UK, patients with LC were age-matched to healthy individuals who contracted SARS-CoV2, recovered without manifesting LC, and received a self-administered psychomotor assessment on their laptops [65,66]. Patients with LC showed about three standard deviations slower reaction times compared to the control.…”

Section: Biomarkers For Severe Cognitive Slowingmentioning

confidence: 99%

Long COVID: Long-Term Impact of SARS-CoV2

Makhluf,

Madany,

Kim

2024

Diagnostics

View full text Add to dashboard Cite

Four years post-pandemic, SARS-CoV-2 continues to affect many lives across the globe. An estimated 65 million people suffer from long COVID, a term used to encapsulate the post-acute sequelae of SARS-CoV-2 infections that affect multiple organ systems. Known symptoms include chronic fatigue syndrome, brain fog, cardiovascular issues, autoimmunity, dysautonomia, and clotting due to inflammation. Herein, we review long COVID symptoms, the proposed theories behind the pathology, diagnostics, treatments, and the clinical trials underway to explore treatments for viral persistence, autonomic and cognitive dysfunctions, sleep disturbances, fatigue, and exercise intolerance.

show abstract

Long COVID is associated with severe cognitive slowing: a multicentre cross-sectional study

Cited by 26 publications

References 29 publications

Preventive Intake of a Multiple Micronutrient Supplement during Mild, Acute SARS-CoV-2 Infection to Reduce the Post-Acute COVID-19 Condition: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial

Preventive Intake of a Multiple Micronutrient Supplement during Mild, Acute SARS-CoV-2 Infection to Reduce the Post-Acute COVID-19 Condition: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial

Interdisziplinäres, kollaboratives D-A-CH Konsensus-Statement zur Diagnostik und Behandlung von Myalgischer Enzephalomyelitis/Chronischem Fatigue-Syndrom

Long COVID: Long-Term Impact of SARS-CoV2

Contact Info

Product

Resources

About